Example: Heart Attack

Clinical Trials Sponsored by Ariad Pharmaceuticals

Total 38 results

NCT01650805

Terminated

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Conditions: Chronic Myeloid Leukemia
NCT03596866

Recruiting

An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib

Conditions: ALK+ Advanced NSCLC
NCT03535740

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Conditions: ALK-positive Advanced NSCLC
NCT03420742

Active, not recruiting

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Patients With ALK-Positive or ROS1-Positive Solid Tumors

Conditions: Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
NCT02784158

No longer available

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
NCT02737501

Completed

ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Conditions: Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
NCT02627677

Active, not recruiting

A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia

Conditions: Chronic Phase Chronic Myeloid Leukemia
NCT02467270

Active, not recruiting

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Conditions: Myeloid Leukemia, Chronic, Chronic Phase
NCT02455024

Terminated

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

Conditions: Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
NCT02094573

Completed

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Conditions: Carcinoma, Non-Small-Cell Lung
NCT01874665

Completed

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Conditions: GIST
NCT01667133

Completed

A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
NCT01592136

Approved for marketing

Expanded Access Program of Ponatinib

Conditions: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
NCT01449461

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Conditions: Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung
NCT01207440

Completed

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia; Ph+ Acute Lymphoblastic Leukemia
NCT00660920

Completed

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Conditions: Chronic Myelogenous Leukemia; Hematologic Malignancies
NCT02829840

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Conditions: Leukemia; FLT3-Mutated Acute Myeloid Leukemia; FLT3-Mutated High-Risk Myelodysplastic Syndrome
NCT01935336

Active, not recruiting

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Conditions: Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
NCT01570868

Terminated

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Conditions: Leukemia
NCT01549548

No longer available

Compassionate Use Ponatinib

Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias; Chronic Myeloid Leukemia
NCT01043887

Completed

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Conditions: Healthy Volunteers; Hepatic Insufficiency
NCT01010672

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Conditions: Sarcoma
NCT00836927

Terminated

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Conditions: Advanced Cancers
NCT00818675

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Conditions: Non-Small Cell Lung Cancer
NCT00781846

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Conditions: Solid Tumor